Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated blood pressure in the pulmonary arteries. Despite significant advancements in medical science, it remains a challenging condition to manage due to its diverse etiology and nonspecific clinical presentation.
PH is primarily a disease of the small pulmonary arteries. The pathophysiological hallmarks include vasoconstriction, vascular remodeling, and in situ thrombosis. These changes lead to a progressive increase in pulmonary vascular resistance, culminating in right heart failure if left untreated.
PH often presents with nonspecific symptoms such as dyspnea, fatigue, and syncope. The diagnosis is confirmed by right heart catheterization, demonstrating a mean pulmonary artery pressure of ≥25 mmHg at rest. Non-invasive tests like echocardiography and computed tomography can provide supportive evidence.
Although PH is incurable, treatment aims to improve symptoms, slow disease progression, and enhance quality of life. Therapeutic strategies include vasodilators, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and soluble guanylate cyclase stimulators. In severe cases, lung transplantation may be considered.
Emerging research is exploring novel therapeutic targets, such as the prostacyclin pathway and immune modulation. Personalized medicine, based on genetic and molecular profiling of patients, also holds promise for improving outcomes in PH.
PH is a complex condition requiring a comprehensive understanding of its pathophysiology, clinical presentation, and treatment approaches. As we continue to unravel the intricacies of this disease, it is crucial for medical professionals to stay updated on the latest research and therapeutic developments. This will enable us to provide the best possible care for our patients and improve their quality of life.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation